60 Participants Needed

Optical Coherence Tomography for Fuchs' Dystrophy

DR
HM
Overseen ByHumberto Martinez, COT
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Oregon Health and Science University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial uses a special imaging technology called optical coherence tomography (OCT) to study how corneal swelling affects vision in people with Fuchs' endothelial dystrophy, an eye condition that causes blurry vision. The research aims to predict how vision changes after surgical treatment by observing corneal swelling. People with corneal problems due to Fuchs' dystrophy who haven't had major eye surgery (except for simple cataract surgery) might be a good fit for this study. As an unphased trial, this study offers participants the opportunity to contribute to groundbreaking research that could improve future treatment strategies for Fuchs' dystrophy.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What prior data suggests that optical coherence tomography is safe for observing Fuchs' dystrophy?

Research has shown that Optical Coherence Tomography (OCT) is a safe technology for taking detailed pictures of the eye without invasive procedures. Studies have found that OCT allows doctors to see the layers of the eye, particularly in conditions like Fuchs' dystrophy, without harming patients. As a non-invasive method, OCT avoids surgery or direct contact with the eye, reducing the risk of side effects. No major reports of problems related to OCT have emerged, and patients generally tolerate it well.12345

Why are researchers excited about this trial?

Researchers are excited about using Optical Coherence Tomography (OCT) for Fuchs' Dystrophy because it offers a non-invasive and highly detailed way to look at the layers of the cornea, which is a major improvement over traditional methods like slit-lamp exams. Unlike standard treatments that focus on managing symptoms or require surgical intervention, OCT can provide precise imaging that helps in monitoring the progression of the disease more effectively. This technique could lead to earlier and more accurate diagnoses, potentially guiding better treatment decisions and improving patient outcomes.

What evidence suggests that optical coherence tomography is effective for Fuchs' dystrophy?

Research has shown that optical coherence tomography (OCT) serves as a valuable tool for examining Fuchs' endothelial dystrophy. It captures detailed images of the eye's tissues, enabling doctors to clearly view the cornea's structure. This detailed perspective is crucial for monitoring corneal swelling and assessing changes post-surgery. While OCT is not a treatment, it aids doctors in understanding the disease's impact on the eye. By providing clear images, OCT helps predict corneal changes, guiding treatment decisions for improved outcomes.25678

Who Is on the Research Team?

WC

Winston Chamberlain, MD, PhD

Principal Investigator

Oregon Health and Science University

Are You a Good Fit for This Trial?

Inclusion Criteria

Damaged or diseased corneal endothelium from Fuchs' or PBK
Willingness to commit to required study visits

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Observation

Participants undergo optical coherence tomography (OCT) to quantify corneal edema and predict refractive shift

up to 2 years

Follow-up

Participants are monitored for safety and effectiveness after observation

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Observational Study
  • Optical Coherence Tomography (OCT)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Oregon Health and Science University

Lead Sponsor

Trials
1,024
Recruited
7,420,000+

National Eye Institute (NEI)

Collaborator

Trials
572
Recruited
1,320,000+

Citations

Therapeutic future of Fuchs endothelial corneal dystrophyIntraoperative OCT generates high-resolution images of the ocular tissue, allowing surgeons to obtain detailed anatomy to improve surgical ...
Study Details | NCT04258787 | OCT in Fuchs' DystrophyThis is an observational study using optical coherence tomography (OCT) technology to quantify corneal edema in Fuchs' endothelial dystrophy and predict ...
Corneal Analysis with Swept Source Optical Coherence ...This study focused on defining the characteristic features of keratometry and pachymetry elevation maps based on swept source optical coherence tomography ...
Deep Learning Analysis of Widefield Cornea Endothelial ...To evaluate the use of a deep learning network (DLN) in analyzing widefield specular microscopy (WFSM) images in eyes with Fuchs endothelial corneal dystrophy ( ...
Imaging pathology in archived cornea with Fuchs' ... - NatureImaging pathology in archived cornea with Fuchs' endothelial corneal dystrophy including tissue reprocessing for volume electron microscopy.
Use of Ultra High Resolution Optical Coherence Tomography ...Furthermore, we demonstrated that UHR-OCT could provide a non-invasive in vivo histological analysis of Fuchs' dystrophy and might provide valuable information ...
Emerging Innovations in the Treatment of Fuchs ...High-definition anterior-segment optical coherence tomography (AS-OCT) ... Long-term safety data for regenerative products are likewise scant.
OCT in Fuchs' Dystrophy - ClinicalTrials.VeevaThis is an observational study using optical coherence tomography (OCT) technology to quantify corneal edema in Fuchs' endothelial dystrophy ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security